Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds the Flt3 (CD135) receptor expressed on hematopoietic stem cells (HSCs), early progenitor cells, immature thymocytes and steady-state dendritic cells (DCs) and induces their proliferation, differentiation, development and mobilization in the bone marrow, peripheral blood and lymphoid organs. CDX-301 has an identical amino-acid sequence and comparable biological activity to the previously tested rhuFlt3L, which ceased clinical development over a decade ago. This Phase 1 trial assessed the safety, pharmacokinetic, pharmacodynamic and immunologic profile of CDX-301, explored alternate dosing regimens and examined the impact of rhuFlt3L on key immune cell subsets. Thirty healthy volunteers received CDX-301 (1-75 μg/kg/day) over 5-10 days. One event of Grade 3 community-acquired pneumonia occurred. There were no other infections, dose-limiting toxicities or serious adverse events. CDX-301 resulted in effective peripheral expansion of monocytes, hematopoietic stem and progenitor cells and key subsets of myeloid DCs and plasmacytoid DCs, with no clear effect on regulatory T cells. These data from healthy volunteers support the potential for CDX-301, as monotherapy or in combination with other agents, in various indications including allogeneic HSC transplantation and immunotherapy, but the effects of CDX-301 will need to be investigated in each of these patient populations.
INTRODUCTION
Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds Fms-like tyrosine kinase-3 (Flt3, CD135), which is expressed on hematopoietic stem cells (HSCs), hematopoietic progenitor cells, immature thymocytes and steady-state dendritic cells (DCs), [1] [2] [3] resulting in the proliferation, differentiation, development and mobilization of these cells in the bone marrow, peripheral blood and lymphoid organs. In earlier clinical trials of recombinant human (rhu) Flt3L in autologous HSC transplantation for breast cancer, 4, 5 non-Hodgkin lymphoma and ovarian cancer, 6 rhuFlt3L administered daily for 14 days with GM-CSF or G-CSF produced higher and more sustained levels of hematopoietic progenitor cells (CD34+ and colony-forming cells) in the apheresis product than G-CSF alone.
Mobilization of Flt3 receptor-expressing HSC, myeloid and lymphoid progenitor cells, DCs and especially immature thymocytes 1 may be of particular importance in allogeneic HSC transplantation, where full recovery of a functional immune system is slow and incomplete. 7 Innate immunity, including neutrophils and natural killer (NK) cells, recovers more quickly. However, donor DC competence is somewhat delayed and B-cell and, to a greater extent, T-cell immune reconstitution is quite delayed, potentially accounting for increased opportunistic infection and malignant relapse. CD34+Flt3+ HSCs can reconstitute myelopoiesis and in particular lymphopoiesis in vivo in NOD/SCID mice, 8 indicating that rhuFlt3L may overcome long lasting T-cell deficiencies currently associated with HSC transplantation.
RhuFlt3L increases both the CD11c+ DC and the CD11c − IL-3R+ DC precursors in the blood of healthy volunteers. 9, 10 In studies of rhuFlt3L as an adjuvant for innate or vaccine immunity in cancer patients, [11] [12] [13] [14] [15] rhuFlt3L administered daily for 14 days with repeating monthly cycles was generally well tolerated with increases in circulating DCs; however, neither enhanced immune nor clinical responses were generally observed. RhuFlt3L-expanded DCs expressed low levels of costimulatory molecules required for inducing T-cell activation, suggesting the need for additional DC-activating agents in order to enhance immune responses. [16] [17] [18] Clinical evidence of potential utility in cancer therapy was reported by Fong et al. 19 who used rhuFlt3L to expand DCs in vivo prior to leukapheresis and then loaded rhuFlt3L-expanded DCs with a carcinoembryonic Ag-derived peptide. After immunization with this cellular vaccine, 2 of the 12 patients experienced dramatic tumor regression, 1 patient had a mixed response and 2 had stable disease.
Thus there is an abundance of preclinical and clinical data supporting the use of rhuFlt3L in stem cell mobilization for transplantation, cancer immunotherapy and as a vaccine adjuvant, although additional questions remain to be answered. After a long pause, the clinical development of soluble rhuFlt3L (now designated CDX-301) has been reinitiated using a new manufacturing process including a proprietary Chinese hamster ovary cell production line and serum-free cell culture. CDX-301 was well tolerated in toxicology studies in Cynomolgus monkeys and rats.
This initial clinical study was performed to support the development of CDX-301 for these potential indications.
MATERIALS AND METHODS

Clinical study design
This Phase 1 study was designed to broaden the biological characterization of rhuFlt3L in humans and to investigate mobilization using various doses and schedules of CDX-301. Study objectives were to evaluate the safety, pharmacokinetic, pharmacodynamic and immunological profiles of CDX-301. Specific pharmacodynamic objectives were to determine the effect of CDX-301 on circulating CD34+ stem cells, DCs and DC subsets, regulatory T cells, NK cells and other hematopoietic/immune cells.
Using a standard 3+3 dose-escalating design, sequential cohorts of 3-6 healthy volunteers received CDX-301 by daily SC injection at a dose level of 1, 3, 10, 25 or 75 μg/kg for 5 days (Cohorts 1-5), 25 μg/kg for 7 days (Cohort 6) or 25 μg/kg for 10 days (Cohort 7). Toxicity was graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Dose-limiting toxicity (DLT) was defined as any treatment-related toxicity with severity ⩾ Grade 2, excluding transient Grade 2 injection site reactions and transient asymptomatic Grade 2-3 hematological changes attributed to the expected pharmacodynamic effects of CDX-301. The maximum tolerated dose was defined as the highest dose level at which o2 DLT were observed. Subjects were followed for safety and tolerability through 28 days following the last dose. The protocol (ClinicalTrials.gov identifier: NCT01465139) was approved by the Institutional Review Board (IRB) of The Rockefeller University, and all participants provided informed consent.
Subjects
Male or female healthy volunteers, aged 18-55 years, with body mass index 18-30 kg/m 2 , willing to use contraception and abstain from alcohol were enrolled. Exclusion conditions included significant medical conditions; significant laboratory or electrocardiogram abnormalities; active or chronic infection, including HIV or hepatitis B or C; syphilis acquired within 12 months; herpes zoster within 3 months; asthma requiring inhaled or oral medication within 5 years; clinically apparent or familial history autoimmune disease; history of tuberculosis, positive purified protein derivative, immunodeficiency, thrombosis, abnormally robust scarring reactions or cancer. Subjects who had received immunosuppressive agents within a year; donated blood or received monoclonal Ab-or Igbased fusion proteins within 8 weeks; started any new prescription medications within 6 weeks; or received any non-study vaccination or experimental therapy within 4 weeks were also ineligible.
Flow cytometry of hematopoietic subsets
Peripheral blood mononuclear cells were isolated from heparinized blood using ficoll-hypaque. Peripheral blood mononuclear cells were stained with two cocktails ((reagents from BioLegend, San Diego, CA, USA), unless otherwise indicated); cocktail 1: CD19 (Invitrogen, Carlsbad, CA, USA; clone SJ25-C1), CD3 (Invitrogen; clone S4. C; cells were then stained in permeabilization buffer (eBioscience) with FoxP3 Ab or isotype control for 60 min at 4°C. Washed cells were fixed in 2% formaldehyde and stored at 4°C until analysis, which was performed using an LSR II flow cytometer (BD Biosciences, San Jose, CA, USA). The whole sample was acquired, and analysis was performed using the Flow Jo 9.7 software (Tree Star, Ashland, OR, USA). The gating strategy for analysis of the immune cell subsets is presented in Supplementary Figure S1 (online only).
Immunogenicity and pharmacokinetics
Serum samples were analyzed for the presence of anti-CDX-301 antibodies on day 21 and the end of treatment for all subjects. Additional samples were analyzed on day 14 for subjects receiving 75 μg/kg/day for 5 days and 25 μg/kg/day for 7 or 10 days. In a 'bridging' format immunoassay, CDX-301 was coated directly onto microtiter plate wells, blocked with albumin, incubated with the human serum samples and detected with biotinylated-CDX-301 followed by a streptavidin-horseradish peroxidase conjugate and colorimetric substrate tetramethylbenzidine. A positive response was one above the 95% confidence interval for results from 30 naive, normal human serum samples. Assay sensitivity was determined to be 31 ng/mL using purified polyclonal rabbit anti-Flt3L Ab.
Blood samples for pharmacokinetic analyses were obtained daily throughout treatment (prior to each dose); at 1, 3, 6, 9 and 12 h after the first and last dose; and daily for at least 4 days following treatment. CDX-301 was quantified using an immunoassay in which mouse antihuman Flt3L IgG1 (mAb clone 40416, R&D Systems, Minneapolis, MN, USA) was coated directly onto microtiter plate wells, blocked with albumin, incubated with the serum samples and detected with affinity purified and biotinylated goat anti-human Flt3L polyclonal Ab (R&D Systems) followed by peroxidase-conjugated streptavidin and colorimetric substrate tetramethylbenzidine. Concentrations over the range of 0.62-40 ng/mL were determined relative to CDX-301 standards.
Pharmacokinetic parameters were estimated from the CDX-301 concentrations using a non-compartmental analysis for extravascular administration (model 200, WinNonlin Version 5.3; Pharsight, St Louis, MO, USA). The last three observed concentrations of CDX-301 were used to estimate the terminal-phase disposition rate, and additional time points were included if they improved the least squares correlation coefficient.
CDX-301
CDX-301 was purified from rhuFlt3L expressed in a Chinese hamster ovary cell line using anion exchange, hydrophobic interaction and cation exchange chromatography. CDX-301 was fully characterized with respect to identity, purity and potency using appropriate GMP assays, and testing was conducted to ensure stability.
RESULTS
Dosing and toxicity
Thirty subjects were enrolled and treated with CDX-301 (Table 1) . Overall, CDX-301 was well tolerated. All enrolled subjects completed the planned duration of dosing and 28-day safety follow-up. A single subject receiving CDX-301 at 75 μg/kg/day for 5 days developed community-acquired pneumonia on day 12. This subject had a remote history of community-acquired pneumonia. This episode of pneumonia responded rapidly to antibiotic treatment, and he fully recovered within 2 weeks. Although the attribution to CDX-301 is unclear, the event was considered a DLT due to the temporal relationship to dosing. The cohort was expanded to a total of six subjects, and the study was completed with no additional infections or DLT. Additional treatment-related toxicity was infrequent. Transient lymphadenopathy (Grade 1) was seen in six subjects (25 or 75 μg/kg/day cohorts) and single cases of diarrhea, injection site erythema, folliculitis and dry mouth (all Grade 1) were observed. No anti-CDX-301 Abs were detected in any subject throughout treatment and follow-up. Pharmacokinetics CDX-301 exhibited an absorption profile typical for SC administration. Mean times to maximum serum concentration (Tmax) ranged from 12.9 h at 3 μg/kg/day to 24.1 h at 25 μg/kg/day. Mean maximum serum concentrations (Cmax) on day 1 ranged from 3.7 to 161 ng/mL in subjects administered 3-75 μg/kg/day for 5 days and increased linearly with dose. Similarly, the area under the curve values increased across the entire range in a doseindependent manner. The half-life of the terminal disposition phase was determined following the final dose administration and ranged from 12.3 h at 10 μg/kg/day to 28 h at 75 μg/kg/day. The mean serum concentrations of CDX-301 for each cohort are plotted as a function of time in Figure 1 .
Efficacy and safety of CDX-301 (rhuFlt3L) N Anandasabapathy et al Table 1 . Treatment cohorts in phase I clinical study of CDX-301 2325 (894) 1314 (166) 947 (189) 2553 (580) 2116 (602) 2383 ( 1677 (715) 1553 (441) 708 (263) 1087 (184) 1678 (260) 995 (138) BDCA-2+CD14-, /mL
4008 (1107) 2690 (1986) 5815 (1502) 5814 (1670) 8101 (2329) 6560 (805) 5824 (502) Treg, /mL 3585 (1995) 6131 (3451) 4376 (1237) 3479 (843) 2959 (614) 1574 (502) 1794 ( Efficacy and safety of CDX-301 (rhuFlt3L) N Anandasabapathy et al
Expansion of hematopoietic cell subsets CDX-301 administration produced increases in peripheral blood WBC, which appeared to be driven largely by increases in monocytes (Figure 2 ). Lymphocytes and neutrophils were not greatly affected by CDX-301 (data not shown), although modest increases in neutrophils were observed in the cohort administered 25 μg/kg/day for 10 days. In the lowest dose cohort
(1 μg/kg/day × 5 days), increases in WBC and monocytes were minimal. In the other dose groups receiving 5-7 daily doses, the numbers of WBC and monocytes peaked around day 10 at similar numbers and subsequently declined to baseline over days 10-20.
The cohort with an extended duration of dosing (10 days at 25 μg/kg/day) had significantly increased monocytes and WBC counts. Similarly, the lowest dose of CDX-301 (1 μg/kg/day × 5 days) had minimal effect on circulating CD34+ cells, which include HSCs and hematopoietic progenitor cells (Figure 3) . Although there was noticeable inter-subject variability in CD34+ cell counts, all other dose cohorts had increases in the numbers of circulating CD34+ cells that peaked over days [8] [9] [10] [11] [12] [13] [14] . Compared with the WBC and monocyte populations, the decline in numbers of CD34+ cells appeared somewhat slower, in some cases requiring 420 days to return to baseline values. Dosing for 5 days achieved CD34+ cell counts ⩾ 7000/mL, a level generally thought to be adequate for PBSC transplantation, but this was more consistent with the longer dosing regimens ( Table 2) .
As previously noted (Figure 1 ), administration for 5 days at 75 μg/kg/day resulted in much greater CDX-301 exposure than did 10 days at 25 μg/kg/day; however, the latter produced greater CD34+ cell increases. This indicates that longer duration of dosing, rather than higher concentration of CDX-301 in the circulation, was responsible for the greater expansion of the CD34+ cells. CDX-301 administration for 10 days at 25 μg/kg/day resulted in a 23-fold increase from a mean baseline count of 2.4/μL to a peak of 55.3/μL.
Similarly, the myeloid DC numbers resulting from 10 days of CDX-301 at 25 μg/kg/day exceeded those from 5 days at 75 μg/kg/day (Figure 4 ). CDX-301 administration for 10 days at 25 μg/kg/day resulted in a 130-fold increase in the blood DC Ag-1 (BDCA-1+) population from a mean baseline count of 10.2/μL to a peak level of 1323/μL. For the BDCA-3+ subset, 10 days of CDX-301 at 25 μg/kg/day resulted in a 48-fold increase from a mean baseline count of 0.99/μL to a peak level of 47.5/μL. Except for the lowest dose cohort (1 μg/kg/day × 5 days) that had minimal effects on myeloid DC numbers, all other dose cohorts produced large increases in circulating myeloid DCs.
The results were similar for the expansion of the plasmacytoid BDCA-2+ subset ( Figure 5 ). However in this case, the expansion from 10 days of CDX-301 at 25 μg/kg/day was more similar to that from 5 days of 75 μg/kg/day dosing than for the other subsets analyzed. Again, the lowest dose cohort showed only minimal The Phase I study reported here evaluated daily SC dosing of CDX-301 for 5-10 days, instead of the 14-day regimens frequently used in earlier studies of rhuFlt3L. Consistent with prior studies, 9 CDX-301 was well tolerated and expanded the expected hematopoietic subsets, including CD34+ cells and DCs. The results suggest that it may be possible to utilize shorter dosing regimens to effectively expand the CD34+ cells and key DC populations, including BDCA3+ DCs, an important consideration for HSC transplantation, given that current G-CSF-based regimens utilize a 5-day dosing regimen and shorter regimen durations are generally more convenient for patients. Indeed, in the current study, five daily doses of CDX-301 alone at 25 or 75 μg/kg/day yielded CD34+ cells in numbers (⩾7000/mL) sufficient for use in PBSC transplantation.
It has long been recognized that rhuFtl3L can interact synergistically with other hematopoietic growth factors 21 and thus the combination of CDX-301 with other agents that mobilize hematopoietic cells may provide yet another approach to minimize the duration of CDX-301 administration while effectively expanding the targeted cell populations. In this regard, He et al. 22 recently demonstrated that rhuFlt3L synergized with plerixafor to mobilize CD34+ cells, and these effects were superior to G-CSF alone or in combination with plerixafor. Moreover, grafts mobilized by the rhuFlt3L plus plerixafor combination led to enhanced survival.
Interestingly, although the 75 μg/kg/day × 5 day dose regimen led to the greatest CDX-301 exposure (Figure 1 ), the 25 μg/kg/day × 10 day cohort had the greatest expansion of hematopoietic subsets. This may reflect the fact that many of the targeted Flt3 receptor-expressing cells are localized in the bone marrow where the rates of Flt3L penetration and mobilization of expanded cell populations might control the overall kinetics for the expanded cell populations in the periphery. In addition, the high serum concentrations of CDX-301 achieved by dose levels of 75 μg/kg/day may actually oversaturate the Flt3 receptors on the various hematopoietic subsets leading to a diminished expansion of the Flt3-expressing cells. The active form of Flt3L is a non-covalent homodimer, 23 which presumably can mediate coalescence of cell surface Flt3 receptors leading to intracellular signaling. The coalescence of Flt3 receptors by dimeric Flt3L may be competitively mitigated at very high Flt3L concentrations.
Studies in mice have demonstrated a positive regulatory feedback loop between DCs and Tregs at least partly mediated by Flt3L. A recent assessment of cryopreserved peripheral blood mononuclear cell samples from an earlier trial in melanoma patients 15 found that SC administration of rhuFlt3L at 20 μg/kg/day for 14 days increased the frequency and absolute number of CD4+CD25+FoxP3+ Treg cells in the peripheral blood. 24 In the current study, no clear effects of rhuFlt3L administration on the numbers of Treg cells in peripheral blood were observed consistent with recent in vitro studies. 25 The differences in the expansion of Treg cells between the studies may be due to the longer duration of daily dosing in the earlier study or to other factors not yet identified. If confirmed, a shorter treatment duration may prove advantageous in immunotherapy regimens where an increase in Treg cells would be an undesirable effect of CDX-301 administration.
In summary, in this Phase 1 clinical trial, we demonstrate that the currently clinically available rhFlt3L (CDX-301) was well tolerated and expanded hematopoietic cells, including CD34+ cells and key DC subsets. We demonstrate using revised criteria for DC subset analyses and advanced multiparametric flow cytometry in humans, and using lower doses and shorter duration of CDX-301 in volunteers than in prior studies, that Flt3L efficiently expands monocytes, BDCA1+ and BDCA3+ DCs with ascribed cross-presentation function and plasmacytoid BDCA2+ DCs, in addition to HSC. We further demonstrate that this occurs without an appreciable effect on Treg, NK cells, NK-T cells, B cells and CD4 and CD8 T cells. However, variability was observed among individuals, and larger numbers of subjects would be required to identify smaller effects. The duration of dosing has an important role in the expansion of the various populations and accordingly can be optimized for particular therapeutic indications. CDX-301 dosing regimens of shorter duration than the 14 daily doses used in earlier clinical studies of rhuFlt3L are suitable for further studies in a variety of clinical indications.
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